Latest Breaking News On - Patients with multiple myeloma - Page 1 : comparemela.com

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesGursel aktanData monitoring committeeDrug administrationStatement of merck co incEuropean network for gynecologic oncology trialMerck research laboratoriesFoundation incExchange commissionMerck co incMerck researchBiologics license applicationPrescription drug user fee actEuropean networkGynecologic oncology trialAmong merck

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication .

United statesMerck research laboratoriesDrug administrationMerck co incEuropean society for medical oncologyStatement of merck co incExchange commissionMarjorie greenMerck researchEuropean societyMedical oncologyImportant safety informationSelected important safetyFatal immune mediated adverseSingle agentThyroid disorders

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Rachid bazDepartment of malignant hematologyPentecost family myeloma research centerMoffitt cancer centerMalignant hematologyPatients with multiple myelomaKarmma 3 trial

Black Patients More Likely to Experience Delays in Multiple Myeloma Treatment Initiation

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.

United statesHispanic african americanHispanic whiteCancer medicineEnd resultsPatients with multiple myelomaNon hispanic african americanAffordable care actInflation reduction act

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

Global Phase 3 studies started for bomedemstat , nemtabrutinib , MK-2870 and MK-5684 Comprehensive clinical development programs being initiated for each investigational candidate Demonstrates.

United statesDrug administrationExchange commissionMerck co incAmerican society for hematologyMerck research laboratoriesEuropean medicines agencyStatement of merck co incOrion corporationMarjorie greenMerck researchOrphan drugFast track designationOrphan drug designationPriority medicinesAmerican society